Displaying drugs 11976 - 12000 of 12647 in total
ARO-ANG3
ARO-ANG3 is a subcutaneously administered RNA interference (RNAi)-based investigational medicine targeting angiopoietin-like protein 3 (ANGPTL3). It was granted an orphan drug designation for the treatment of homozygous familial hypercholesterolemia (HoFH).
Investigational
Matched Description: … It was granted an orphan drug designation for the treatment of homozygous familial hypercholesterolemia …
CER-001
CER-001 is a negatively charged lipoprotein particle comprising human recombinant apolipoprotein A-I and two phospholipids: sphingomyelin and dipalmitoylphosphatidylglycerol. It is under investigation for the treatment of lecithin-cholesterol acyltransferase (LCAT) deficiencies.
Investigational
Matched Description: … [L48290] It is under investigation for the treatment of lecithin-cholesterol acyltransferase (LCAT) deficiencies …
AVR-RD-04
AVR-RD-04 is an investigational gene therapy for cystinosis. It consists of autologous CD34+ enriched cells transduced with a lentiviral vector containing RNA resulting in codon-optimized cDNA encoding for functional human cystinosin.
Investigational
Matched Description: … It consists of autologous CD34+ enriched cells transduced with a lentiviral vector containing RNA resulting …
BGT-DTDS
BGT-DTDS is an investigational gene therapy comprising an adeno-associated viral vector type 2 (AAV2) encoding the human SLC6A3 gene. It is under investigation for the treatment of dopamine transporter deficiency syndrome (DTDS).
Investigational
Matched Description: … It is under investigation for the treatment of dopamine transporter deficiency syndrome (DTDS). …
Mevidalen
Mevidalen is under investigation in clinical trial NCT03305809 (A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)).
Investigational
Matched Description: … Mevidalen is under investigation in clinical trial NCT03305809 (A Study of LY3154207 in Participants …
ADL 10-0101
ADL 10-0101 is a peripheral kappa opioid agonist analgesic product candidate. Preclinical trials of ADL 10-0101 have suggested that the compound may be effective for the treatment of inflammatory pain, itch and visceral pain. Because ADL 10-0101 does not cross the blood-brain barrier and enter the brain when administered at...
Investigational
Matched Description: … of inflammatory pain, itch and visceral pain. ... Preclinical trials of ADL 10-0101 have suggested that the compound may be effective for the treatment …
Astaxanthin
Astaxanthin is a keto-carotenoid in the terpenes class of chemical compounds. It is classified as a xanthophyll but it is a carotenoid with no vitamin A activity. It is found in the majority of aquatic organisms with red pigment. Astaxanthin has shown to mediate anti-oxidant and anti-inflammatory actions. It may...
Investigational
Matched Description: … It is found in the majority of aquatic organisms with red pigment. ... Astaxanthin is a keto-carotenoid in the terpenes class of chemical compounds. …
WIN 55212-2
WIN 55,212-2 is a chemical described as an aminoalkylindole derivative, which produces effects similar to those of cannabinoids such as tetrahydrocannabinol (THC) but has an entirely different chemical structure. It is a potent cannabinoid receptor agonist that has been found to be a potent analgesic in a rat model of...
Experimental
Matched Description: … is a chemical described as an aminoalkylindole derivative, which produces effects similar to those of ... is a potent cannabinoid receptor agonist that has been found to be a potent analgesic in a rat model of …
Viral Macrophage-Inflammatory Protein
Viral macrophage inflammatory protein-II (vMIP) is a highly basic protein and human chemokine analog encoded by human herpesvirus-8. The structure of vMIP consists of 71 residues and is a monomer under most conditions. It helps its virus evade the host immune system through selectively blocking and activating different receptors, preferentially...
Investigational
Matched Description: … The structure of vMIP consists of 71 residues and is a monomer under most conditions. …
Danvatirsen
Danvatirsen is under investigation in clinical trial NCT03334617 (Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.).
Investigational
Matched Description: … Danvatirsen is under investigation in clinical trial NCT03334617 (Phase II Umbrella Study of Novel Anti-cancer …
Inarigivir
Inarigivir is under investigation in clinical trial NCT03434353 (Study to Evaluate the Antiviral Activity of Inarigivir (GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)).
Investigational
Matched Description: … Inarigivir is under investigation in clinical trial NCT03434353 (Study to Evaluate the Antiviral Activity of …
Gastric inhibitory polypeptide
Gastric inhibitory polypeptide is under investigation in clinical trial NCT03081676 (The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea).
Investigational
Matched Description: … Gastric inhibitory polypeptide is under investigation in clinical trial NCT03081676 (The Effect of GIP …
JNJ-54175446
JNJ-54175446 is under investigation in clinical trial NCT02933762 (A Study in Healthy Participants to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and Plasma).
Investigational
Matched Description: … investigation in clinical trial NCT02933762 (A Study in Healthy Participants to Evaluate the Effect of …
Dovramilast
Dovramilast is under investigation in clinical trial NCT01300208 (To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus).
Investigational
Matched Description: … (To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of …
SEA-CD70
SEA-CD70 is an investigational humanized, non-fucosylated monoclonal antibody targeting CD70. SEA-CD70 is under investigation in clinical trial NCT04227847 (A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies).
Investigational
Matched Description: … SEA-CD70 is under investigation in clinical trial NCT04227847 (A Safety Study of SEA-CD70 in Patients …
COVID19 s-vax loaded autologous dendritic cell vaccine
Dendritic cells (DCs) can be derived and differentiated from peripheral blood mononuclear cells in the presence of specific cytokines and growth factors. These cells are then loaded with antigens produced by a virus or tumor cell and administered as a vaccine.
Dendritic Cells (DCs) are showing potential as natural adjuvants...
Investigational
Matched Description: … and immunogenicity of the vaccine. ... cells (DCs) can be derived and differentiated from peripheral blood mononuclear cells in the presence of ... As of May 2020, the company is pursuing a human clinical trial (ChiCTR2000033003) to test the safety …
SARS-CoV-2 Sclamp
The University of Queensland (UQ), in partnership with The Coalition for Epidemic Preparedeness Inovations (CEPI) and CSL has developed a COVID-19 candidate, SARS-CoV-2 Sclamp. The vaccine was developed using UQ’s rapid response ‘molecular clamp’ vaccine platform that locks surface proteins in a configuration that allows more robust immune responses, in...
Investigational
Matched Description: … The University of Queensland (UQ), in partnership with The Coalition for Epidemic Preparedeness Inovations ... Preclinical trials showed the vaccine candidate produced high levels of neutralizing antibodies, and ... As of July 13, 2020, the candidate is being tested for safety and immunogenicity in Phase 1 clinical …
TAK-475
TAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been brought to market.
Investigational
Matched Description: … TAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been …
CMC 001
CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.
Investigational
Matched Description: … CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile …
AMG-208
AMG-208 has been used in trials studying the treatment of Cancer, Tumors, Oncology, Prostate Cancer, and Oncology Patients, among others.
Investigational
Matched Description: … AMG-208 has been used in trials studying the treatment of Cancer, Tumors, Oncology, Prostate Cancer, …
Onartuzumab
Onartuzumab has been used in trials studying the treatment of Neoplasms, Lung Cancer, Glioblastoma, Gastric Cancer, and Colorectal Cancer, among others.
Investigational
Matched Description: … Onartuzumab has been used in trials studying the treatment of Neoplasms, Lung Cancer, Glioblastoma, Gastric …
Blisibimod
Blisibimod has been used in trials studying the treatment of IgA Nephropathy, Microscopic Polyangiitis, Systemic Lupus Erythematosus, and Granulomatosis With Polyangiitis.
Investigational
Matched Description: … Blisibimod has been used in trials studying the treatment of IgA Nephropathy, Microscopic Polyangiitis …
AZD-8055
AZD8055 has been used in trials studying the treatment of Cancer, Lymphomas, Solid Tumors, MALIGNANT GLIOMA, and brainstem glioma, among others.
Investigational
Matched Description: … AZD8055 has been used in trials studying the treatment of Cancer, Lymphomas, Solid Tumors, MALIGNANT …
Cobitolimod
Cobitolimod is under investigation in clinical trial NCT03178669 (The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis).
Investigational
Matched Description: … Cobitolimod is under investigation in clinical trial NCT03178669 (The Efficacy of Cobitolimod in Patients …
Codrituzumab
Codrituzumab is under investigation in clinical trial NCT01507168 (A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma).
Investigational
Matched Description: … Codrituzumab is under investigation in clinical trial NCT01507168 (A Study of RO5137382 (GC33) in Patients …
Displaying drugs 11976 - 12000 of 12647 in total